



Capital investment in immuno-oncology field



Source: Pitchbook Data, Inc.



Cancer immunotherapy clinical trials trend



Source: NIH ClinicalTrial.gov


© 2023 ACS Proprietary and Confidential






How did we identify the connections?

Expert scientists combined with a wide range of ML tools to optimize connections



The rapidly evolving field of cancer immunotherapy


Overall publication and citation trends




Source: CAS Content Collection



Journal publication trends by country/ region






Source: CAS Content Collection





Patent publication trends by country/ region




Source: CAS Content Collection

© 2023 American Chemical Society. All rights reserved.




Emerging concepts growth in journal publication





CAS Patent Trend Landscape

Cancer types





Source: CAS Content Collection




Target trends

Journal landscape












Target trends

Patent landscape










Target proteins


Fast growing while still in early phase





Inhibitory immune checkpoint molecules


Overall publications trends (Title/Abstract)





Stimulatory immune checkpoint molecules


Overall publications trends (Title/Abstract)





CAS emerging therapy trends


Journal landscape






CAS emerging therapy trends

Patent landscape









Acknowledgement

CAS colleagues and teammates

- Kavita Iyer
- Yacid Rodriguez
- Julian Ivanov
- Krittika Ralhan
- Qiongqiong Angela Zhou






Gain insights on emerging therapies and more



Sabina Scott LS Capability Owner sscott2@cas.org



Executive Summaries



Journal Publications

Subscribe to stay connected:

www.cas.org/insights

linkedin.com/company/cas



